Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC
Laura M. Spring(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Veerle Bossuyt(Harvard University), Beverly Moy(Global Cancer Institute), Bogang Wu(George Washington University), Jacob Geisberg(Harvard University), Mengran Zhang(Harvard University), Nicole Peiris(Harvard University), Siang‐Boon Koh(Harvard University), Aditya Bardia(UCLA Health), Lianne Ryan(Harvard University), James T. Coates(Harvard University), Sara M. Tolaney(Harvard University), Simona Cristea(Harvard University), Franziska Michor(Dana-Farber Cancer Institute), Steven J. Isakoff(Harvard University), Ting Liu(Harvard University), Rachel O. Abelman(Massachusetts General Hospital)
Cited by 2
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k